bullish
Wuxi Biologics (2269 HK): 2024 Revenue Meets Guidance; Poised for Accelerated Growth in 2025
243 Views26 Mar 2025 16:13
Wuxi Biologics reports 10% revenue growth in 2024, with non-COVID business up 13% YoY. The company guides for 12-15% revenue growth in 2025, with improving profitability.
What is covered in the Full Insight:
- Introduction
- 2024 Financial Performance
- Geographical and Segment Analysis
- Operational Improvements and Challenges
- Conclusion and Investor Considerations
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Related Insights
More »- WuXi Biologics (2269 HK) - Strong Demand to Drive Growth Acceleration in 2025
- Wuxi Biologics (2269 HK) - The Concerns Behind 2024 Results and the Outlook in 2025
- Wuxi Biologics (2269 HK): 2024 Revenue Meets Guidance; Poised for Accelerated Growth in 2025
- WuXi Biologics (2269 HK) - Promising Demand Boding Well for 2025
- China Healthcare Weekly (Jan.5)-TCM VBP Update, Medical Device VBP Result Is Out, WuXi Bio's Outlook
Trending Collections
More »Loading
Trending Insights
More »- The Hidden Play in Hanwha’s Noisy Stake Reshuffling: Hanwha Corp’s Rights Issue
- Hang Seng Indexes: FAF Methodology Change for Secondary Listings; Over US$1bn to Buy in NetEase
- Korea Short Selling: Off to the Races
- Nikkei 225 Mar25 Rebal - A Big Buy With Buying Shadow, A Bigger Sell, And $2bn of Funding Flows
- Merger Arb Mondays (31 Mar) - ENN Energy, ESR, Vesync, Seven & I, Topcon, Sinarmas Land, Gold Road
Top Unpaywalled Insights
More »Loading
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Wuxi Biologics (2269 HK): 2024 Revenue Meets Guidance; Poised for Accelerated Growth in 202526 Mar 2025
x